Records containing: Solid Tumors
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2019-09-25A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-09-20A Phase I Study of Vinblastine and Sirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors Including CNS Tumors
-
CLINICAL_TRIALS study record update · 2019-09-19A Multicenter, Open-Label, Phase 1 Trial of SHR3162 Given Orally to Subjects With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-09-12Patient Registry for Prospective Research on Evolving Radiation Oncology Techniques and Quality
-
CLINICAL_TRIALS study record update · 2019-09-11A Phase I Open-label Multicentre Dose-escalation Study of Subcutaneous ALM201 in Patients With Advanced Ovarian Cancer and Other Solid Tumours
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2019-09-03Phase I Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered CUDC-907, an HDAC and PI3K Inhibitor, in Subjects With Advanced/Relapsed Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-08-28Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients
-
CLINICAL_TRIALS study record update · 2019-08-22A Phase 1 Dose Escalation and Cohort Expansion Study of ERY974, An Anti-Glypican3 (GPC3)/CD3 Bispecific Antibody, in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-07-23An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-07-22Phase 1, Open-label Study to Assess the Safety, Tolerability, and Pharmacokinetics of DS-8895a in Subjects With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-07-18Official Title: A Phase 1B/2 Study of the Safety and Tolerability of Itacitinib (INCB039110) in Combination With Gemcitabine and Nab-Paclitaxel in Subjects With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-07-17A Phase I Study of High-dose, Intermittent Sunitinib in Patients With Solid Tumors.
-
CLINICAL_TRIALS study record update · 2019-06-24An Open-label, Non-randomised, Multicentre Study to Allow Continued Access to and Assess the Safety and Tolerability of AZD1775 for Patients Enrolled in AZD1775 Clinical Pharmacology Studies
-
CLINICAL_TRIALS study record update · 2019-06-19A Multi-Center, Open-Label, Clinical Pharmacology Study for Idasanutlin, an MDM2 Antagonist With a Hybrid Randomized/Sequential, Single-Dose, 4-Period, Crossover Design to Investigate the Bioequivalence or Relative Bioavailability of Three New Idasanutlin Tablet Variants Following Oral Administration in Patients With Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-05-22A First-in-Human Phase I Single-Agent Open-Label Dose-Escalation Study of Every Three-Week Dosing of Oral ONC201 in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-05-06A Phase 1, First-in-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered AMG 900 in Adult Subjects With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-04-25An Open-Label, Phase 1/1b, Single-Agent Study of RXDX-105 in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-04-05A Phase I Dose Escalation Study Evaluating MK-1775 in Both Monotherapy and in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adult Subjects With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-03-26A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas
-
CLINICAL_TRIALS study record update · 2019-03-25Study of the Effect of Esomeprazole or Rifampin on the Pharmacokinetics of Alisertib and Evaluation of the Effect of Alisertib on the QTc Interval in Patients With Advanced Solid Tumors or Lymphomas
-
CLINICAL_TRIALS study record update · 2019-03-19Phase I/II Study Using Epitope Peptide Restricted to HLA-A*24 or HLA-A*02 in Patients With Advanced Solid Tumors That Are Refractory to Standard Therapy
-
CLINICAL_TRIALS study record update · 2019-03-15A Phase 1b Study of LY573636-sodium in Combination With Alimta (Pemetrexed) in Patients With Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-03-01A Phase I Study of Ridaforolimus in Pediatric Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-03-01A Phase 1 Dose-Escalation Study of LY2603618 in Combination With Gemcitabine in Japanese Patients With Solid Tumors
-
CLINICAL_TRIALS study record update · 2019-02-26A First in Human Phase I Study of INVAC-1 as a Single Agent in Patients With Advanced Cancer